GH Stock Price Today (October 2026) — Guardant Health, Inc. Analysis & Key Metrics 2026-10-07
Guardant Health, Inc. (GH) is trading at $168.33, down 1.38% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $197.04 (17.1% upside).
- Volatility is high (42.43% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (44.30% YoY) alongside competitive pressures in the Diagnostics & Research space.
GH Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Guardant Health, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $23.23B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+17.1% upside potential
Key Investor Questions About GH
What investors need to know before buying
Based on current market data, GH presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 43.15)
- Fundamentals say: Mixed signals (nuanced financial profile)
GH's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for GH investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $1.70B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, GH stock traded between $61.00 and $183.51 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 42.43% annualized volatility and β=0.90, the stock exhibits moderate correlation to market moves—making GH suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.
Guardant Health has also earned a spot on the Investor's Business Daily Leaderboard. Earlier this month, the FDA approved Guardant360 CDx as a companion diagnostic for Etcamah from AstraZeneca in advanced or metastatic breast cancer. Guardant360 CDx is the first FDA-approved liquid biopsy CDx for longitudinal testing in breast cancer.
Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role
Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic in advanced HR-positive, HER2-negative breast cancer. The decision makes Guardant360 CDx the first FDA approved liquid biopsy companion diagnostic for longitudinal ctDNA testing in breast cancer care. The approval is supported by clinical trial data where early detection of ESR1 mutations using Guardant360 CDx informed treatment changes for patients. The Guardant360 CDx breast...
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) and its peers.
Guardant Health Nears Buy Point As Sales Outlook Brightens
Guardant Health provides services across the cancer continuum. Shares are near a buy point of 176.58 after a breakout.
Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says
Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the re
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks
During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 98 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Upg
1 Growth Stock to Add to Your Roster and 2 We Turn Down
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
What Makes Guardant Health (GH) a Compelling Bet?
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection
Guardant Health, Inc. (NASDAQ:GH) faces a costly legal setback after a US court ordered the cancer-testing company to pay more than $245.2 million in a DNA-sequencing patent dispute. The final judgment upheld a 2023 jury verdict finding that Guardant willfully infringed two DNA-sequencing patents asserted by TwinStrand Biosciences and the University of Washington. The financial […]
Guardant Health (GH) Stock Could Trade At A 21% Discount Despite Patent Appeal
Guardant Health stock has delivered very strong gains over the past three years, yet its valuation signals are split, with the intrinsic value estimate pointing to upside while broader checks suggest the shares are not a clear bargain. After a recent legal setback and a sharp multi year rise, investors are weighing how much of Guardant Health’s growth potential is already reflected in the current price. Guardant Health has returned about 327.6% over the past three years, which puts more...
Explore More Analysis for GH
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Guardant Health, Inc.
Guardant Health, Inc. (GH) is currently trading at $168.33. The RSI (14-day) is at 43.2, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $197.04 implies 17.1% upside from current levels. Volatility is high at 42.4% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Guardant Health, Inc. (GH): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Sales is 19.04. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering GH, the consensus price target is $197.04. This represents a 17.1% upside from the current price of $168.33. The range spans from a low target of $105.00 to a high target of $225.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Guardant Health, Inc. (GH) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Guardant Health, Inc. (GH) investors include: 1. High volatility (42.4% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Guardant Health, Inc.'s (GH) current debt and financial health profile: Total debt stands at $1.70B. The current ratio is 4.03, indicating strong short-term liquidity. The quick ratio is 3.53. The company holds $1.05B in cash and equivalents. Free cash flow is positive at $26.61M, providing a cushion for debt servicing and shareholder returns.